NUVISAN events

Speakers & Hosts

Nuvisan congress De-Risking Clinical Trials: Gain in-depth Understanding of your Drug

December 1-2, 2021 from 4:00 PM CET to 6:00 PM CET

Speakers

Carlo Stresemann is a specialist on pharmacology, target validation and chemical biology in cancer. Prior to joining NUVISAN in 2020, he gathered his experience working for 12 years within research pharmacology at BAYER AG, where he started as a lab head leading drug discovery programs from early target validation until clinical development. He pioneered the field of epigenetic research at BAYER but also led projects targeting different other cancer pathways including survival signalling, metabolism, apoptosis, and cancer stem cells. Carlo is a Biologist by training and graduated from Heidelberg University. He holds a PhD since 2008 for studying DNA methylation changes and DNA methyltransferase inhibitors as therapeutic approach in cancer at the German Cancer Research Center (DKFZ) in Heidelberg. At Nuvisan, Carlo leads the Therapeutic Oncology Research group.

Heidi Greulich received her undergraduate degree in molecular biology from Princeton University and her PhD in molecular oncology from The Rockefeller University and embarked upon a career in cancer research spanning academia, industry, and collaborations between the two.  At the Dana-Farber Cancer Institute and Broad Institute, Dr. Greulich studied oncogenic mutations in protein kinase genes, including EGFR, ERBB2, FGFR2, and ARAF.  More recently, as a Senior Group Leader at the Broad Institute, she has been focusing on the discovery and development of a new class of small molecules, called velcrins, that kill cancer cells by a completely new mechanism: induction of complex formation between PDE3A and SLFN12.  Testing of this therapeutic hypothesis in clinical trials is now underway in collaboration with Bayer.  Dr. Greulich is on the editorial board of Cancer Research and has been a keynote speaker for the annual Lung Cancer Research Foundation Cancer Awareness Luncheon in New York.

Spyros Stamatelos, PhD, is currently Senior Director of Clinical Pharmacology within the Research and Early Development organization of Bayer. Dr. Stamatelos was a Group Leader/Director within the translational medicine and data science organizations at Sanofi US, with a focus on developing mathematical models for oncology and immuno-oncology (I/O) applications. Dr. Stamatelos received his PhD from Rutgers University in biomedical engineering in 2010 with focus on systems biology of arsenic-induced hepatotoxicity. Following graduation, he completed a 4-1/2 years postdoctoral fellowship at Johns Hopkins School of Medicine focusing on breast cancer angiogenesis. He worked as a Senior Scientist at the Icahn School of Medicine at Mount Sinai and Roche Pharmaceuticals until his move to Sanofi in 2016. Dr. Stamatelos’s work has focused on multiscale mathematical model development for solid tumors and hematologic malignancies, and virtual population algorithms to support regulatory filing and internal decision making within translational medicine and clinical pharmacology organizations. His work has successfully supported regulatory filing of multiple oncology assets.

Sebastian Dieter studied medicine in Freiburg, Heidelberg, Strasbourg and Boston. As a medical PhD student in the group of professor Hanno Glimm at the National Center for Tumor Diseases (NCT) and the German Cancer Research Center (DKFZ) in Heidelberg, he characterized the clonal composition of colorectal cancer stem cells. In a first postdoc phase, he continued working on gastrointestinal cancers with a more translational focus, identifying novel vulnerabilities and treatment approaches including drug development projects with colleagues from Bayer/Nuvisan. After his board certification in internal medicine and hematology/oncology, he joined the group of professor Reuven Agami at the Netherlands Cancer Institute (NKI) in Amsterdam for a second postdoc, working on genetic screens and systematic approaches for overcoming drug resistance. Since 2021, he works as a physician scientist at the NCT and DKFZ Heidelberg with combined translational research and clinical activities.

Christian studied biology at the Free University Berlin, Germany, where he obtained his diploma in 1981 and his PhD graduation in Zoology and Biochemistry in 1984. He joined Schering AG, Berlin, Germany, as a Scientist in the department of Contrast Media Pharmacology in 1984. In 1986, he moved to the department Pharmacokinetics at Schering AG, Berlin, where he worked on bioanalysis of steroid hormones, conducted in vivo and in vitro studies and did pharmacokinetic analyses in clinical studies. Christian became a Scientific Expert in Human Kinetics Fertility Control/Hormone Therapy at Schering AG in 2001 and worked as a non-clinical representative in several development projects. Following the acquisition of Schering AG by Bayer AG in 2006, he worked as Senior Pharmacokinetics Expert in the function Clinical Pharmacokinetics Women’s Healthcare, Diagnostics and Specialized Therapeutics. In 2010, he was assigned as Principal Scientist at Bayer AG. In 2012, he moved to Clinical Pharmacology Oncology where he is currently working as Clinical Pharmacology Lead supporting several projects.

Andreas has more than 20 years of experience in Drug Discovery DMPK. He is VP - Head DMPK modelling and simulation and currently heads DMPK M&S, prior he headed Research PK which was responsible for the complete DMPK support of all drug discovery projects across diverse therapeutic areas from lead generation until preclinical candidate selection & profiling. Andreas holds a PhD in Cell Biology from Leipzig University. During his PostDoc at King’s College London, funded by several pharmaceutical companies, he worked on in vitro models and in silico approaches to assess and predict the CNS penetration of drugs. Andreas then joined Discovery DMPK at Hoffmann-La Roche, Basel, where he expanded his area of expertise to intestinal and hepatic transport processes and their relevance for drug absorption, drug disposition and drug-induced liver injury. Having a passion for scientific innovations he has been supervising >10 Master and PhD students. His latest research interests are in the fields of PK/PD of new modalities, microphysiological systems, oral absorption modelling and drug delivery technologies.

Sven Christophe Golfier serves Nuvisan ICB as principal scientist in Translational Research. He has 16 years of experience in pharmaceutical industry and a strong record in preclinical drug development. He dedicated 10 years to the cancer research and the development of antibody drug conjugates from the discovery to the clinic. He expanded his wide-ranging experience in drug development in translational biomarker research for indication profiling and patient identification. Sven holds a Ph.D. in biochemistry

Michael Niehues received his undergraduate and Phd degree in food chemistry with Prof. Andreas Hensel from the Westfälische Wilhelms University Münster (Germany). After graduating, he joined the University of São Paulo (Brazil) for a postdoc, working on In vitro and in vivo metabolism of natural compounds, mass spectrometry and gas phase reactions. In 2013, Michael joined Bayer AG, Wuppertal and Berlin (Germany) as Lab Head mainly focusing cold and radiolabelled Metabolite ID, phenotyping of Drug Metabolizing Enzymes and MS Imaging. He also joined in 2017 Bayer AG fellowship program at Uppsala University (Sweden) with Prof. Per Andrén to work on MALDI-MS Imaging research activities. Since 2020, he is the Head of Structure and Sample Analytics at Innovation Campus Berlin (Germany).

Hosts

Dr. Charlotte Kopitz is Biologist by training with a passion for applied research. She started academic research in the field of natural pest control/Zoology, followed by basic research on the autoimmune disease sprue, followed by a PhD as well as Postdoc in the field of Experimental Oncology. In 2008 she took over the lead of an in vivo Laboratory in Oncology Research at Bayer, with increasing repertoire and responsibilities, incl. project leadership along the value chain, membership of the Global Bayer Animal Welfare Committee and Inclusion and the role as Inclusion & Diversity Advisor of the Bayer Pharma R&D organization. In 2019 she took over the responsibility for Pharmacology of the Innovation Campus Berlin at Bayer, preparing the transition to NUVISAN GmbH. At July 1st 2020 she became EVP and Head of Therapeutic Research in the Innovation Campus Berlin as part of the NUVISAN family.

Olaf has more than 25 years of experience in drug discovery and development. He currently heads the department of Preclinical Compound Profiling within Nuvisan ICB, which encompasses ICB’s entire expertise in DMPK and toxicology as well as animal management and welfare. Prior to this position he headed Drug Metabolism Berlin within Bayer AG. Olaf holds a PhD in Organic Chemistry from the university in Münster, Germany, and worked afterwards as a post-doc in Vic Snieckus‘ lab in Canada, investigating ortho-lithiation and synthesis of highly subsituted aromatic derivaties before joining Schering AG late 1996 in the area of combinatorial chemistry and lab automation. He continued as a medicinal chemist and lead the large-scale resynthesis lab. In 2007 he moved into DMPK area and took over the drug metabolism group in Berlin in 2008, where he was also responsible for supporting all local drug discovery and selected development projects, from preclinical up to submission, including interaction with authorities. In 2019 he accepted the responsibility in his current position, where he was deeply involved in the transition of DMPK and toxicology functions and respective staff from Bayer to the Innovation Campus Berlin. From mid 2020 onwards he actively accompanied his team in the service-oriented world of the Nuvisan Science CRO. His more recent activities also include the set-up of a freshly accredited GLP organization within the ICB.